Hepatitis B Screening (HBsAg)
Last reviewed 25 August 2026 · Evidence-graded review — see Methodology
A test whose risk calculus is genuinely different in Singapore from the countries most longevity content is written for. Chronic hepatitis B is a leading cause of cirrhosis and liver cancer, stays silent for decades, and is treatable — and prevalence among people born in East and Southeast Asia is far higher than in the Western populations that shape default screening advice.
Krist AH, Davidson KW, et al. (US Preventive Services Task Force) “Screening for Hepatitis B Virus Infection in Adolescents and Adults.” JAMA 2020;324:2415–2422 issues a Grade B recommendation to screen adolescents and adults at increased risk, a group explicitly defined to include people born in regions with HBsAg prevalence of 2% or higher — which covers much of the region Singapore draws its population from. A positive result leads to antiviral treatment and to hepatocellular carcinoma surveillance, both of which change outcomes.
Krist AH, et al. JAMA. 2020. PubMed: PMID 33320230
Singapore guidance
Not covered in the current review
Singapore’s national screening committee has not reviewed this test in the current volume of its report, which covers nine conditions. That is not a verdict either way.
Source: Screening Test Review Committee report 2026, Volume 1 (Academy of Medicine Singapore and Ministry of Health, February 2026). The full national list · How this is used.
What you would actually pay
- Healthier SG
- Not subsidised
- MediSave
- Not among the screenings named for outpatient claims
Source: Healthier SG Screening (HealthHub) and MediSave outpatient care (Ministry of Health). Absence from either list is not a statement that the test is discouraged — only that no subsidy or claim applies. Gross prices compared.
What it costs when it is wrong
- Basis
- No published harm criterion found
- Severity
- Not documented
Not covered in the current volume of the committee’s report, so no harm criterion was found either way.
An empty finding, not a clean bill of health: this means nothing documented was found for this test. It is not a claim that the test is safe.
Screening harm is not only a laboratory question: the committee’s own criteria advise against a test when “the screening test, or follow-up tests arising from a positive screen, are associated with significant medical risks”. Sources on overdiagnosis → · How this is graded.
FAQ
Is the Hepatitis B Screening (HBsAg) worth doing in Singapore?
The evidence behind Hepatitis B Screening (HBsAg) is graded strong for screening an asymptomatic adult. Most appropriate for anyone born in, or with parents from, a high-prevalence region — which includes a large share of Singapore's population. It typically costs S$20–45 in Singapore. The usual schedule: once, if never previously tested and not known to be vaccinated.
Weighing this against something else? Compare it with two other tests → · Price it inside a panel →